JO3336B1 - مركبات أمينو بيريديلوكسي بيرازول - Google Patents
مركبات أمينو بيريديلوكسي بيرازولInfo
- Publication number
- JO3336B1 JO3336B1 JOP/2015/0235A JOP20150235A JO3336B1 JO 3336 B1 JO3336 B1 JO 3336B1 JO P20150235 A JOP20150235 A JO P20150235A JO 3336 B1 JO3336 B1 JO 3336B1
- Authority
- JO
- Jordan
- Prior art keywords
- cancer
- compounds
- aminopyridyloxypyrazole
- fibrosis
- glioblastoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
يتعلق الاختراع الحالي بمركبات أمينو بيريديلوكسي بيرازول جديدة تثبط نشاط مستقبل بيتا لعامل النمو المتحول 1 (TGF?R1)، وتركيبات صيدلية تشتمل على المركبات، وطرق استخدام المركبات لعلاج السرطان، وبشكل مفضل، سرطان القولون، الميلانوما، كارسينوما الخلايا الكبدية، السرطان الكلوي، الورم الأرومي النخاعي، سرطان البنكرياس، متلازمة خلل التنسج النخاعي، سرطان الرئة، وسرطان معدي، و/أو التليف، وبشكل مفضل، تليف الكبد وداء الكلى المزمن.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462060724P | 2014-10-07 | 2014-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3336B1 true JO3336B1 (ar) | 2019-03-13 |
Family
ID=54266692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2015/0235A JO3336B1 (ar) | 2014-10-07 | 2015-09-22 | مركبات أمينو بيريديلوكسي بيرازول |
Country Status (42)
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015089800A1 (en) | 2013-12-19 | 2015-06-25 | Eli Lilly And Company | Fluorophenyl pyrazol compounds |
CA2935392C (en) | 2014-01-01 | 2022-07-26 | Medivation Technologies, Inc. | Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity |
CN106795120B (zh) * | 2014-10-31 | 2020-09-01 | 豪夫迈·罗氏有限公司 | 新的吡啶基氧基-和苯基氧基-吡唑基化合物 |
EP3518926A1 (en) * | 2016-09-30 | 2019-08-07 | Eli Lilly and Company | USE OF 2-{4-[(4-{[1-CYCLOPROPYL-3-TETRAHYDRO-2H-PYRAN-4-yl)-1H-PYRAZOL-4-yl]OXY}PYRIDINE-2-yl)AMINO]PYRIDIN-2-yl}PROPAN-2-OL IN THE TREATMENT OF CANCER |
JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
EP3600294A4 (en) | 2017-03-23 | 2020-08-26 | Clavius Pharmaceuticals, LLC | TRI-SUBSTITUTED IMIDAZOLES FOR INHIBITION OF TGF-BETA AND TREATMENT METHODS |
WO2019013790A1 (en) * | 2017-07-12 | 2019-01-17 | Curza Global, Llc | ANTIMICROBIAL COMPOUNDS AND USES THEREOF |
CN107540672A (zh) * | 2017-10-10 | 2018-01-05 | 牡丹江医学院 | 一种治疗肝硬化的药物及其合成方法 |
CN108912103A (zh) * | 2018-01-21 | 2018-11-30 | 吕迎春 | 一种2-乙酸酯咪唑类化合物及其在防治骨质疏松药物中的应用 |
CA3103771A1 (en) * | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
US20210309679A1 (en) | 2018-07-23 | 2021-10-07 | Guangzhou Othrotx Co., Ltd. | Bisphosphonate drug conjugates |
EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF |
WO2020041562A1 (en) * | 2018-08-22 | 2020-02-27 | Clavius Pharmaceuticals, Llc | Substituted imidazoles for the inhibition of tgf-beta and methods of treatment |
AU2019362242A1 (en) * | 2018-10-18 | 2021-05-27 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Compound as TGF-β R1 inhibitor and application thereof |
WO2020088526A1 (zh) * | 2018-10-31 | 2020-05-07 | 南京明德新药研发有限公司 | 作为TGF-βR1激酶抑制剂的双环吡唑类化合物 |
WO2020103817A1 (zh) * | 2018-11-20 | 2020-05-28 | 南京圣和药业股份有限公司 | TGF-βR1抑制剂及其应用 |
CN113348167A (zh) | 2018-12-27 | 2021-09-03 | 奈可萨斯医药有限公司 | 用于治疗癌症的作为TGF-βR1(ALK5)抑制剂的(吡啶-2-基)胺衍生物 |
AU2020207391A1 (en) * | 2019-01-10 | 2021-06-24 | Sumitomo Pharma Oncology, Inc. | ALK5 inhibitors for treating myelodysplastic syndrome |
EP3922631A4 (en) * | 2019-01-24 | 2022-10-26 | Jiangsu AoSaiKang Pharmaceutical Co., Ltd. | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS AS A TGF-BETA R1 KINASE INHIBITOR |
WO2020258006A1 (en) * | 2019-06-25 | 2020-12-30 | Inventisbio Shanghai Ltd. | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof |
CN112694477B (zh) * | 2019-10-22 | 2024-02-06 | 四川科伦博泰生物医药股份有限公司 | 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途 |
WO2021129621A1 (zh) * | 2019-12-23 | 2021-07-01 | 江苏先声药业有限公司 | 吡唑类化合物 |
CN111116565B (zh) * | 2020-04-01 | 2020-07-14 | 中科利健制药(广州)有限公司 | 2-芳基-4-(4-吡唑氧基)吡啶类化合物、其制备方法、药物组合物与应用 |
CN111303135A (zh) * | 2020-04-01 | 2020-06-19 | 中科利健制药(广州)有限公司 | 4-(4-吡唑氧基)喹啉类化合物、其制备方法、药物组合物与应用 |
WO2021204626A1 (en) | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
CN113698395B (zh) * | 2020-05-22 | 2023-12-08 | 赛诺哈勃药业(成都)有限公司 | 转化生长因子受体拮抗剂、其制备方法和应用 |
CN114867723B (zh) * | 2020-07-23 | 2023-05-30 | 江苏奥赛康药业有限公司 | 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 |
WO2023182780A1 (ko) * | 2022-03-22 | 2023-09-28 | 오토텔릭바이오 주식회사 | 티아졸 유도체 화합물 및 이의 용도 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002339268B2 (en) | 2001-05-24 | 2007-05-31 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
WO2013086397A1 (en) | 2011-12-08 | 2013-06-13 | Array Biopharma Inc. | Urea compounds as gka activators |
WO2015089800A1 (en) | 2013-12-19 | 2015-06-25 | Eli Lilly And Company | Fluorophenyl pyrazol compounds |
-
2015
- 2015-09-22 TW TW104131319A patent/TWI582083B/zh not_active IP Right Cessation
- 2015-09-22 JO JOP/2015/0235A patent/JO3336B1/ar active
- 2015-09-23 AR ARP150103058A patent/AR102003A1/es unknown
- 2015-09-30 MY MYPI2017701190A patent/MY190541A/en unknown
- 2015-09-30 EP EP15777845.7A patent/EP3204377B1/en active Active
- 2015-09-30 US US14/870,033 patent/US9617243B2/en active Active
- 2015-09-30 NZ NZ729800A patent/NZ729800A/en unknown
- 2015-09-30 WO PCT/US2015/053098 patent/WO2016057278A1/en active Application Filing
- 2015-09-30 RS RS20181372A patent/RS58094B1/sr unknown
- 2015-09-30 EA EA201790476A patent/EA031830B1/ru not_active IP Right Cessation
- 2015-09-30 TR TR2018/16415T patent/TR201816415T4/tr unknown
- 2015-09-30 AU AU2015328553A patent/AU2015328553C1/en not_active Ceased
- 2015-09-30 CN CN201580054343.9A patent/CN106795139B/zh active Active
- 2015-09-30 CA CA2961262A patent/CA2961262C/en active Active
- 2015-09-30 MX MX2017004457A patent/MX367360B/es active IP Right Grant
- 2015-09-30 BR BR112017005453-1A patent/BR112017005453B1/pt active IP Right Grant
- 2015-09-30 UA UAA201702921A patent/UA118807C2/uk unknown
- 2015-09-30 SI SI201530417T patent/SI3204377T1/sl unknown
- 2015-09-30 PL PL15777845T patent/PL3204377T3/pl unknown
- 2015-09-30 AP AP2017009836A patent/AP2017009836A0/en unknown
- 2015-09-30 LT LTEP15777845.7T patent/LT3204377T/lt unknown
- 2015-09-30 CR CR20170072A patent/CR20170072A/es unknown
- 2015-09-30 SG SG11201702481UA patent/SG11201702481UA/en unknown
- 2015-09-30 JP JP2016526891A patent/JP6043894B2/ja active Active
- 2015-09-30 ES ES15777845T patent/ES2700376T3/es active Active
- 2015-09-30 TN TN2017000046A patent/TN2017000046A1/en unknown
- 2015-09-30 PE PE2017000536A patent/PE20170662A1/es unknown
- 2015-09-30 DK DK15777845.7T patent/DK3204377T3/en active
- 2015-09-30 MA MA41038A patent/MA41038B1/fr unknown
- 2015-09-30 PT PT15777845T patent/PT3204377T/pt unknown
- 2015-09-30 KR KR1020177009123A patent/KR101921847B1/ko active IP Right Grant
-
2017
- 2017-02-09 IL IL250543A patent/IL250543B/en active IP Right Grant
- 2017-02-16 ZA ZA2017/01175A patent/ZA201701175B/en unknown
- 2017-03-10 CO CONC2017/0002233A patent/CO2017002233A2/es unknown
- 2017-03-24 SV SV2017005411A patent/SV2017005411A/es unknown
- 2017-03-30 DO DO2017000090A patent/DOP2017000090A/es unknown
- 2017-03-30 CL CL2017000765A patent/CL2017000765A1/es unknown
- 2017-04-04 GT GT201700067A patent/GT201700067A/es unknown
- 2017-04-06 EC ECIEPI201721097A patent/ECSP17021097A/es unknown
- 2017-04-06 PH PH12017500635A patent/PH12017500635B1/en unknown
-
2018
- 2018-10-30 HR HRP20181797TT patent/HRP20181797T1/hr unknown
- 2018-11-13 CY CY20181101193T patent/CY1120903T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500635B1 (en) | Aminopyridyloxypyrazole compounds | |
PH12018500457A1 (en) | New phenoxymethyl derivatives | |
MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
MX2017013075A (es) | Conjugados de farmaco que comprenden anticuerpos contra claudina 18.2. | |
MX2021011939A (es) | Compuestos neuroactivos y metodos de uso de los mismos. | |
NZ731789A (en) | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | |
NZ737399A (en) | Ccr2 modulators | |
JO3155B1 (ar) | معدِّل نكهة حلوة | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
MX2016010447A (es) | Composiciones y metodos para tratar diabetes y enfermedades hepáticas. | |
MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
MX2018001315A (es) | Inhibidores de fucosidasa. | |
MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
GB201912986D0 (en) | Novel drugs for the treatment of metastatic solid tumours | |
EA201791264A1 (ru) | Соединения для лечения злокачественного новообразования | |
TR201401730A2 (tr) | Artroz'un semptomatik tedavisine yönelik bir kompozisyon. |